Tripchlorolide May Improve Spatial Cognition Dysfunction and Synaptic Plasticity after Chronic Cerebral Hypoperfusion

Zhao-Hui Yao,1 Xiao-li Yao,2 Shao-feng Zhang,3 Ji-chang Hu,4 and Yong Zhang3

1Department of Geriatrics, Renmin Hospital of Wuhan University, #238 Jiefang Road, Wuhan, China
2Department of Neurology, Central Hospital of Zhengzhou, #195 Tongbo Road, Zhengzhou, China
3Department of Neurology, Renmin Hospital of Wuhan University, #238 Jiefang Road, Wuhan, China
4Department of Pathology, Renmin Hospital of Wuhan University, #238 Jiefang Road, Wuhan, China

Correspondence should be addressed to Zhao-Hui Yao; yaozhaohui2004@126.com

Received 13 September 2018; Revised 10 November 2018; Accepted 16 December 2018; Published 24 February 2019

Academic Editor: Clive R. Bramham

Copyright © 2019 Zhao-Hui Yao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chronic cerebral hypoperfusion (CCH) is a common pathophysiological mechanism that underlies cognitive decline and degenerative processes in dementia and other neurodegenerative diseases. Low cerebral blood flow (CBF) during CCH leads to disturbances in the homeostasis of hemodynamics and energy metabolism, which in turn results in oxidative stress, astrogial overactivation, and synaptic protein downregulation. These events contribute to synaptic plasticity and cognitive dysfunction after CCH. Tripchlorolide (TRC) is an herbal compound with potent neuroprotective effects. The potential of TRC to improve CCH-induced cognitive impairment has not yet been determined. In the current study, we employed behavioral techniques, electrophysiology, Western blotting, immunofluorescence, and Golgi staining to investigate the effect of TRC on spatial learning and memory impairment and on synaptic plasticity changes in rats after CCH. Our findings showed that TRC could rescue CCH-induced spatial learning and memory dysfunction and improve long-term potentiation (LTP) disorders. We also found that TRC could prevent CCH-induced reductions in N-methyl-D-aspartic acid receptor 2B, synapsin I, and postsynaptic density protein 95 levels. Moreover, TRC upregulated cAMP-response element binding protein, which is an important transcription factor for synaptic proteins. TRC also prevented the reduction in dendritic spine density that is caused by CCH. However, sham rats treated with TRC did not show any improvement in cognition. Because CCH causes disturbances in brain energy homeostasis, TRC therapy may resolve this instability by correcting a variety of cognitive-related signaling pathways. However, for the normal brain, TRC treatment led to neither disturbance nor improvement in neural plasticity. Additionally, this treatment neither impaired nor further improved cognition. In conclusion, we found that TRC can improve spatial learning and memory, enhance synaptic plasticity, upregulate the expression of some synaptic proteins, and increase the density of dendritic spines. Our findings suggest that TRC may be beneficial in the treatment of cognitive impairment induced by CCH.

1. Introduction

Chronic cerebral hypoperfusion (CCH) is a critical mechanism in the development of vascular cognitive impairment and dementia. It is the common underlying pathophysiological mechanism that contributes to cognitive decline and degenerative processes in dementia and other neurodegenerative diseases [1]. CCH promotes the progression of vascular cognitive impairment to dementia and accelerates the development of Alzheimer’s disease (AD). Low cerebral blood flow (CBF) in CCH changes the homeostasis of hemodynamics and reduces the availability of oxygen, glucose, and other nutrients in the brain. This leads to disturbances in the homeostasis of energy metabolism [2, 3], which in turn leads to cerebrovascular remodeling, degeneration of the neurovascular unit and trophic coupling [4], energy loss in neurons, and vulnerability to the internal and external environment.

Previous studies have shown that CCH exacerbates neurodegeneration via multiple mechanisms, including the induction of oxidative stress which involves fatty acids, proteins, DNA, and mitochondria, blood-brain barrier
disruption, increases in neuronal Ca\(^{2+}\) [5], Aβ accumulation and aggravation [6], tau hyperphosphorylation, synaptic dysfunction, neuronal loss, white matter lesions, release of neuroinflammatory cytokines [7–9], excessive autophagy [10], and overactivation of microglia in the hippocampus [11, 12]. These events lead to mitochondrial dysfunction via activation of mitophagy, changes in mitochondrial morphology due to imbalance in fusion and fission events [10, 13, 14], disturbances in lipid metabolism [15], disruption of the integrity of the white matter and fiber disarrangement of the white matter [16, 17], alterations in growth factor expression [15], inhibition of neurogenesis [18], and neurotransmitter system dysfunction [2]. Furthermore, CCH can lead to the downregulation of synaptic proteins and demyelination and the reduction of dendritic spines in the hippocampus, which then leads to a reduction in synaptic transmission and neuroplasticity [12, 19, 20]. Eventually, these pathophysiological mechanisms can result in the development of cognitive dysfunction.

Tripchlorolide (TRC), an herbal extract of Tripterygium, is a small molecule that is modified by chlorode and has a molecular weight of 397. It has potent anti-inflammatory and immunosuppressive functions. Given that TRC has good lipophilicity and small molecular weight characteristics, TRC can easily pass through the blood-brain barrier and play a role in the brain [21–23]. Treatment with TRC may inhibit lipopolysaccharide-induced release of inflammatory proteins in the brain [24]. TRC may also suppress BACE1 activity which may attenuate β-amyloid generation [25], as well as protect neurons from microglia-mediated beta-amyloid neurotoxicity by attenuating neuroinflammatory responses [23]. Moreover, TRC has been shown to protect dopaminergic neurons from neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in a Parkinson’s disease (PD) model and prevent the reduction in dopamine levels in the striatum [26]. This neuroprotective effect is thought to be due to the anti-inflammatory and antioxidant properties of TRC [22]. In addition, TRC treatment also ameliorated defective spatial learning and memory and increased the expression of synapse-related proteins in familial AD (5XFAD) mice [27]. TRC has also been shown to improve age-associated cognitive deficits, impaired hippocampal long-term potentiation (LTP), and synapse-related receptor dysfunction in senescence-accelerated transgenic mice [21].

Given these neuroprotective effects, it is reasonable to hypothesize that TRC may improve CCH-induced cognitive impairment, although to date, no relevant investigations have been conducted. Therefore, in order to determine whether TRC can improve cognitive impairment induced by CCH, we examined the effect of TRC on spatial learning and memory impairment, as well as on changes in synaptic plasticity in rats exposed to CCH.

## 2. Materials and Methods

### 2.1. Antibodies and Chemicals.

The mouse monoclonal antibody (mAb) against total β-actin used in this study was purchased from Abcam (Cambridge, CB, UK), while the rabbit polyclonal antibody (pAb) against vesicular glutamate transporter (vGLUT) used was purchased from Synaptic Systems (Göttingen, Germany). The rabbit pAb for N-methyl-D-aspartic acid (NMDA) receptor 2A (NR2A) used in this study was also obtained from Abcam (Cambridge, CB, UK). The rabbit pAb for postsynaptic density protein 95 (PSD95), postsynaptic density protein 93 (PSD93), NMDA receptor 2A (NR2A), NMDA receptor 2B (NR2B), glutamate receptor 1, and synapsin 1, as well as the mouse mAb against NMDA receptor 1 (NR1), the mouse mAb against cAMP-response element binding protein (CREB), the phosphorylated CREB (p-CREB), the goat anti-rabbit IgG (H+L) secondary antibody Alexa Fluor 488 conjugate, and the goat anti-mouse IgG (H+L) secondary antibody Alexa Fluor 647 conjugate were all purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). The mouse mAb against glutamate receptor 2 (GluR2) used in the study was purchased from Millipore Corp. (Billerica, MA, USA). The goat anti-rabbit and anti-mouse IgG conjugated to IRDye800 (800CW) were purchased from LI-COR Biosciences (Lincoln, NE, USA). The BCA protein assay kit used in the study was from Pierce Chemical Company (Rockford, IL, USA).

Tripchlorolide was purchased from Seebio Biotechnology, Ltd. (Shanghai, China) and dissolved in saline to a concentration of 0.1 μg/ml for use.

### 2.2. Animals, Chronic Cerebral Hypoperfusion (CCH) Model, and Drug Treatment.

Adult Sprague-Dawley rats (male, 220–240 g) were obtained from Hunan SJA Laboratory Animal Co., Ltd. and were housed with accessible food and water ad libitum. Rats were kept on a 12 h light/dark cycle with the light on from 7:00 am to 7:00 pm. The Ethics Committee of Renmin Hospital of Wuhan University approved all animal care protocols and experiments.

For anesthesia, rats were intraperitoneally injected with chloral hydrate (0.4 g/kg). The permanent bilateral carotid artery occlusion or two-vessel occlusion (2VO) procedure was performed as previously described [28]. After a ventral midline incision, both common carotid arteries were gently separated from the carotid sheath and vagus nerve [11] on a 37°C heating pad. The bilateral common carotid arteries were doubly ligated with a 4-0 silk suture just below the carotid bifurcation. In control rats, a similar surgery was performed but the vessel was not ligated. After the surgery was completed, the rats were kept in a room maintained at a temperature of 37°C until they recovered. A laser Doppler system was used to detect the level of blood flow and ensure that it had been reduced to 70% below normal, which is an important criterion of the 2VO model. CBF was measured in the cortices to reflect the perfusion of the whole brain before and after the 2VO surgery. After the rats were anesthetized with urethane (1.6 g/kg, i.p.), the skull skin was cut to expose the skull. The laser Doppler flowmetry probe was placed directly on the skull, 3.0 mm posterior to the bregma and 3.2 mm lateral to the midline, to record the CBF perfusion level.

On the third day following the 2VO surgery, the rats were intraperitoneally injected with 1 μg TRC/kg every day for 28 days [21, 26, 27]. The same volume of saline was used for the sham-treated rats.
2.3. Morris Water Maze. After 30 days of cerebral hypoperfusion, all rats completed spatial memory training in the Morris water maze. The experiment was conducted as previously described [29]. The rats were trained in the water maze to find a hidden platform. This training is comprised of four trials per day with a 30 s intertrial interval between 2:00 and 8:00 pm for seven consecutive days. Each trial started with the rat placed in the middle of the outer edge of one quadrant and facing the wall of the pool and ended when the animal climbed onto the platform. Rats that could not find the platform in 60 s were guided to the platform. The Morris water maze video tracking analysis system (Shanghai, China) was used to record the activity trajectory of the rats. The swimming paths of the rats and latencies of the rats to find the hidden platform were recorded [30]. The time the rat spent before arriving at the platform during the first trial on each day over a seven-day period was recorded as the latency time. Upon removal of the platform, which occurred during the fourth trial on each day over the seven-day period, the number of times the rats passed through the platform area was recorded. The latency time and the number of times the rat crossed the platform area were used to evaluate learning ability. After one day of rest, the short-term memory retention test was performed. The platform was either present or absent, and rats were put into the third quadrant of the maze. The latency to reach the platform area, the number of times that the platform area was crossed, and the total time that the rat spent in the platform quadrant were recorded.

2.4. Novel Object Recognition Test (NOR Test). The NOR test was performed as previously described [31]. The NOR test, which is based on the natural tendency to explore a novel object more than a familiar one [32], was used to evaluate short-term memory deficits. The rats were placed in a 55 cm × 55 cm × 38 cm open-field box made of black Plexiglas. On day 1, two objects were symmetrically placed in the box, and the rats were allowed to habituate to these objects. They were also allowed to explore and familiarize themselves with the open-field arena for 20 min. On day 2, two novel objects were placed at diagonal corners in the box, and the rats were allowed to explore these two similar objects for 5 min. On day 3, one of the two familiar objects from day 2 was replaced with a novel object to form a pair of novel and old objects. To evaluate the memory retention of the familiar and novel objects, the rats were allowed to explore the two objects for 5 min. The new object recognition experimental video analysis system (Shanghai, China) was used to record the time spent exploring each object. The ratio of the time spent exploring the novel or old object to the total time spent exploring both objects was calculated. The exploration discrimination index was calculated as the time exploring the novel object versus the old object over the total time spent exploring both objects ((time exploring the novel object - time exploring the old object)/(time exploring the novel object + time exploring the old object) * 100%) [33, 34].

2.5. Electrophysiology. Synaptic plasticity is the critical physiological basis of learning and memory. Enhancement or weakening of synaptic plasticity can improve or reduce learning and memory abilities. LTP is an important form of synaptic plasticity. Therefore, to investigate the underlying mechanisms of cognitive impairment, we recorded the field potential of the brain in order to analyze the changes in LTP. After the spatial memory retention test, rats were anesthetized with urethane (1.6 g/kg, i.p.). The electrophysiological procedure was performed as previously described [28]. ELECTRODES were implanted at the following coordinates: 3.3 mm posterior to the bregma and 3.6 mm lateral to the midline for the recording electrode and 6.9 mm posterior to the bregma and 4.0 mm lateral to the midline for the stimulating electrode. The ground electrode was connected to the muscle contralateral to the electrode sites. Recordings of field excitatory postsynaptic potentials (fEPSPs) were made from pyramidal neurons of the Cornu Ammonis (CA) 3 region in response to the stimulation of the perforant path (PP). The data acquisition system was triggered simultaneously to record all events. The sampling frequency was 3 kHz for fEPSP recordings. The high frequency stimulation (HFS) protocol for inducing long-term potentiation (LTP) consisted of 10 trains of 15 stimuli (200 Hz, 0.5 mA) with 5 s intervals. This rather weak LTP induction protocol was chosen to prevent saturation of LTP and to thus allow for the possibility of detecting improvements or impairments. The slope of a 10 min fEPSP recording prior to the application of the HFS was used as the baseline fEPSP slope. LTP was measured as normalization of the 40 min fEPSP slope recorded after the application of the HFS over baseline fEPSP slope. And the relative values of post-HFS were further analyzed. Data were analyzed with Igor Pro 6.1 (WaveMetrics, Lake Oswego, Oregon) software.

2.6. Western Blotting. For Western blotting, rats were decapitated and the hippocampi were rapidly removed and homogenized. The extract was mixed with sample buffer, heated for 10 min and then centrifuged at 12,000 × g for 10 min at 25°C. The protein concentration was estimated using a bicinchoninic acid (BCA) kit. Proteins were separated using 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and were subsequently transferred onto nitrocellulose membranes. The membranes were blocked with 5% nonfat milk and probed overnight with a primary antibody at 4°C, incubated with anti-rabbit or anti-mouse IgG conjugated to IRDye™ (800CW) (1 : 10000) for 1 h at 4°C, and visualized using the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA).

2.7. Immunofluorescence. Rats were anesthetized with an overdose of chloral hydrate (1 g/kg) and perfused. Their brains were then fixed and embedded with paraffin. Brains were cut into 5 μm thick sections and placed on slides. The sections of rat brains were blocked with 0.3% H₂O₂ in absolute methanol for 10 min, followed by antigen retrieval with citric acid buffer. Nonspecific sites were blocked with bovine serum albumin (BSA) for 30 min at room temperature. The sections were then incubated overnight at 4°C with primary antibodies (1 : 200). After washing with PBS, the sections were subsequently incubated with Alexa Fluor
immuno-recognition tests. Electrophysiological tests were then performed to record the fEPSP and evaluate LTP. Finally, biochemistry, evaluate the dendritic spine density.

o particles on the surface of the tissue block were brushed solution was changed every 24 hours. Afterwards, the silver nitrate solution for another three days. The silver nitrate was rinsed o
do times, the dye solution on the surface of the tissue block post
do of neurons under a fluorescence microscope.

2.8. Golgi Staining. For Golgi staining, rats were anesthetized and perfused through the aorta for 30 min continuously with 100 ml 0.9% NaCl containing 0.5% NaN₃O, 250 ml 4% paraformaldehyde solution, followed by 250 ml 4% paraformaldehyde solution containing 5% potassium bichromate and 5% chloral hydrate (Golgi stain). Brains were removed, cut into small pieces of tissue with volumes of 5 mm³, and postfixed in Golgi stain for three days. After rinsing three times, the dye solution on the surface of the tissue block was rinsed off and the blocks were dried using a filter paper. Subsequently, the blocks were immersed into a 1.5% silver nitrate solution for another three days. The silver nitrate solution was changed every 24 hours. Afterwards, the silver particles on the surface of the tissue block were brushed off, and the blocks were cut into 50 μm thick sections. After the sections were dehydrated, cleared, and mounted, they were observed under oil immersion microscopy. Two to three dendrites from each of the 10 different cells per animal were analyzed. Spines were counted while manually changing the focus in order to identify all spines on a particular dendrite. Spine density was defined as the density of all spines counted per animal divided by the total length of the dendrite. It was expressed as the number of spines identified per μm dendrite. The number of mushroom and filopodia spines was counted and divided by the total length of the dendrite and expressed as the number of spines identified per 100 μm of dendrite. This was used as a measure of the density of mushroom and filopodia spines.

3. Results

3.1. TRC Treatment Rescues Spatial Learning and Memory Impairment in a Morris Water Maze Test after CCH. To determine whether TRC can ameliorate cognitive impairment caused by CCH, rats were exposed to 30 days of chronic cerebral hypoperfusion induced by a 2VO surgery, followed by 28 days of TRC treatment (Figure 1), after which their spatial learning and memory abilities were examined using a Morris water maze test. The results showed that rats which underwent 2VO surgery had a noticeably longer latency time to reach the platform from the third to the seventh training day than rats which underwent sham surgery (p < 0.01) (Figure 2(a)). Rats which underwent 2VO surgery and TRC treatment (2VO + TRC group) had a shorter latency time from the third to the seventh training day than rats that only underwent 2VO surgery (2VO group) (days 3-4, p < 0.05; days 5-7, p < 0.01) (Figure 2(a)). During the seven-day maze learning task, the training heatmap showed that the number of times the 2VO rats crossed the platform area in 60 s was significantly less than that of the sham animals (p < 0.01) (Figure 2(b)), but the rats that underwent 2VO surgery and TRC treatment crossed the platform area more times than rats that underwent 2VO only (days 3, 6, and 7, p < 0.01; days 4-5, p < 0.05) (Figure 2(b)). After seven days of training and one day of rest, the short-term memory test revealed that rats which underwent 2VO surgery had a significantly longer latency time to reach the platform than sham rats (p < 0.01), whereas rats which underwent 2VO surgery and TRC treatment took significantly less time to reach the platform (p < 0.05) (Figure 2(c)). Once the platform was removed, rats which underwent 2VO surgery spent less time in the platform quadrant than sham rats (p < 0.01), and rats which underwent 2VO surgery and TRC treatment spent more time in the platform quadrant than rats that underwent only 2VO surgery (p < 0.01) (Figure 2(d)). Furthermore, rats that underwent 2VO surgery crossed the platform area fewer times than sham rats (p < 0.01), and rats that underwent 2VO surgery and were subsequently treated with TRC crossed the area more times than 2VO rats that did not undergo TRC treatment (p < 0.01) (Figure 2(e)).
3.2. TRC Treatment after CCH Rescues Spatial Learning and Memory Impairment in the Novel Object Recognition Test.

In order to further understand the effect of TRC on the spatial learning and memory abilities of rats, the novel object recognition (NOR) test was used. The results showed that rats that underwent 2VO surgery spent significantly more time with the old object than the sham-treated rats ($p < 0.01$), but rats that underwent 2VO surgery and TRC treatment spent significantly less time with the old object than rats that underwent 2VO surgery only ($p < 0.05$) (Figure 3(a)). Accordingly, the rats that underwent 2VO surgery spent much less time with the new object than the sham rats ($p < 0.01$), but rats that underwent 2VO surgery and TRC treatment spent less time with the new object than rats that underwent 2VO only ($p < 0.05$) (Figure 3(b)). The final calculations revealed that rats that underwent 2VO surgery had a markedly low recognition discrimination index when compared to sham-treated rats ($p < 0.01$), but rats that underwent 2VO surgery and TRC treatment had a significantly higher recognition discrimination index than rats that underwent 2VO surgery only ($p < 0.01$) (Figure 3(c)).

3.3. TRC Treatment Improves the LTP Deficit after CCH.

Long-term potentiation (LTP) reflects synaptic plasticity which was the physiological basis for hippocampus-dependent spatial learning and memory [35] and is indispensable for hippocampus-dependent spatial learning and the formation and retrieval of hippocampus-dependent spatial memory [36]. To investigate the underlying electrophysiological mechanisms of the effect of TRC on cognitive impairment induced by CCH, we performed in vivo electrophysiology. After high frequency stimulation (HFS), we recorded the field excitatory postsynaptic potentials (fEPSPs). The fEPSP amplitudes were remarkably lower in
ment induced by CCH, we examined CREB expression whether CREB plays a role in the spatial cognitive impair-
downregulation leads to cognitive decline [41, 42]. To clarify
important for memory formation [40]. Moreover, CREB
controls the expression of many synaptic proteins. It plays a
key role in neuronal excitability and controls the hippocam-
pus and cortex plasticity circuits [38, 39]. CREB is very
important for memory formation [40]. Moreover, CREB
downregulation leads to cognitive decline [41, 42]. To clarify
whether CREB plays a role in the spatial cognitive impair-
ment induced by CCH, we examined CREB expression

3.4. TRC Treatment Prevents CCH-Induced Downregulation
of Synaptic Proteins. Synaptic proteins are important com-
ponents of synaptic structure formation. They are involved in vesicle synthesis, transport, and release and normal syn-
aptic function. Synaptic protein expression is critical for
synaptic plasticity and the maintenance of normal learning and memory [37]. To explore the potential molecular
mechanism of CCH-induced learning and memory impair-
ment, we used Western blotting to examine the expression
of synapse-related molecules. Our data showed that NR1, NR2A, PSD93, GluR1, and GluR2 in the 2VO group did
not change significantly compared to those in the sham
group \((p > 0.05)\) (Figures 4(a) and 4(b)). The NR2B, synap-
sin I, and PSD95 levels in the 2VO group were significantly
lower than those in the sham group \((p < 0.01)\), but the expression of these same proteins in the 2VO+TRC group
was significantly higher than in the 2VO group \((p < 0.05)\)
(Figures 4(a) and 4(b)).

3.5. TRC Treatment Prevents CCH-Induced Downregulation
of Phosphorylated CREB. CREB is a transcription factor that
controls the expression of many synaptic proteins. It plays a
key role in neuronal excitability and controls the hippocam-
pus and cortex plasticity circuits [38, 39]. CREB is very
important for memory formation [40]. Moreover, CREB
downregulation leads to cognitive decline [41, 42]. To clarify
whether CREB plays a role in the spatial cognitive impair-
ment induced by CCH, we examined CREB expression
using Western blotting. We did not find any change in the
CREB level. Because phosphorylated CREB (p-CREB) is
the active form of CREB, we further evaluated the p-CREB
level. The data showed that p-CREB levels in rats which
underwent 2VO surgery were significantly lower than those
in sham-treated rats \((p < 0.01)\), but rats that underwent
2VO surgery and TRC treatment had much higher
p-CREB levels than rats that underwent 2VO surgery only
\((p < 0.01)\) (Figures 5(a) and 5(b)). To further understand
the distribution of p-CREB in the subregions of the hippo-
campus, we performed immunofluorescence staining of
p-CREB in brain slices and found that rats that underwent
2VO surgery had a significantly lower mean optical inten-
sity of p-CREB staining in the CA3 and CA1 regions, dentate
gyrus, and cortex than sham-treated rats \((p < 0.01)\), whereas rats that underwent 2VO surgery and TRC treat-
ment had a significantly higher mean optical intensity of
p-CREB staining in these regions \((p < 0.01)\) (Figures 6(c)
and 6(d)).

3.6. TRC Treatment Rescues the Reduction in Dendrite Spine
Density after CCH. Dendritic spines are important locations
for the formation of neuronal circuits and network struc-
tures. A reduction in dendritic spine density is bound to
reduce synapse formation and thus impair cognitive function
[43]. Our previous study showed that CCH can lead to a
reduction in dendritic spine density by using the Golgi
stain to label and display dendritic spines. The data showed
that rats that underwent 2VO surgery had a noticeably lower
density of dendritic spines in hippocampal neurons than
sham-treated rats \((p < 0.01)\), but the rats that underwent
2VO surgery and TRC treatment had a higher density of
dendritic spines than rats that underwent 2VO surgery only \((p<0.01)\) (Figures 7(a) and 7(b)). Mushroom spines are mature spines and are necessary for neuronal synapse formation. The density of mushroom spines can determine the number of synapses that have formed. Our data showed that rats which underwent 2VO surgery had a noticeably lower density of mushroom spines than sham-treated rats \((p<0.01)\), whereas rats that underwent 2VO surgery and TRC treatment had a higher density of mushroom spines than rats which underwent 2VO surgery only \((p<0.01)\) (Figures 7(c) and 7(d)).

4. Discussion

In the present study, we show that TRC can rescue CCH-induced spatial learning and memory dysfunction and improve LTP disorders. Additionally, we found that TRC can prevent the reduction in NR2B, synapsin I, and PSD95 expression that occurs in response to CCH. Moreover, TRC leads to an upregulation in p-CREB levels. p-CREB is an important transcription factor for synaptic proteins. TRC prevented the CCH-induced reduction in dendritic spine density.

LTP of synaptic transmission is a form of long-term synaptic plasticity [44] and is important for circuit refinement during memory formation and behavioral changes [45]. LTP can be quickly induced with a persistent increase in synaptic efficacy after high frequency stimulation [46]. Learning can enhance LTP [47], and LTP have also been shown to enhance learning and memory in transgenic models [48]. Impairment of LTP can lead to spatial memory deficits [49]. Alleviating deficits in hippocampal long-term potentiation improved memory in a rat model of Alzheimer’s disease [50]. In our study, we found that TRC treatment improves CCH-induced LTP impairment, which suggests that TRC increased the efficacy of synaptic transmission in neuronal circuits and rescued the CCH-induced synaptic plasticity deficits. Previous studies have shown that TRC can stimulate brain-derived neurotrophic factor (BDNF) mRNA expression [26]. Endogenously secreted BDNF affects synaptic plasticity [51], regulates synaptic transmission and long-term potentiation (LTP) in the hippocampus, and plays a role in the formation of memory [52]. This suggests that TRC may improve the CCH-induced impairment in synaptic plasticity by regulating the expression of hippocampal endogenous BDNF. This will be explored and verified in future research. In our previous study, we demonstrated that chronic neuroinflammation in brain tissues after CCH treatment can impair cognition. Moreover, CCH induces memory impairment and accelerates Aβ generation [9, 53]. Interestingly, TRC produces anti-inflammatory effects by downregulating extracellular signal-regulated protein kinases 1/2 (ERK1/2) nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and JAK/STAT signaling pathways [24, 54]. TRC

\[\text{Relative field excitable postsynaptic potential in hippocampus} \]

\[\begin{align*}
\text{Pre-HFS} & \quad \text{Post-HFS} \\
\text{Con} & \quad \text{2VO + TRC} \\
\text{TRC} & \\
\end{align*}\]

Figure 4: TRC treatment improves the CCH-induced LTP deficit. After completing the behavioral tests, the rats were anesthetized, and recording and stimulating electrodes were implanted with stereotaxic localization. The baseline fEPSP and the fEPSP after HFS were recorded (a). The relative fEPSP slope was then calculated (b). Con: sham group \((n=11)\); 2VO: the group with bilateral common carotid artery ligation \((n=10)\); 2VO+TRC: the 2VO group treated with 1 μg tripchlorolide/kg \((n=10)\); TRC: the sham group treated with 1 μg tripchlorolide/kg \((n=11)\). Data are expressed as means ± SEM. \(^* p<0.05\), \(^{**} p<0.01\) compared with the Con group, \(^{#} p<0.05\), \(#^{**} p<0.01\) compared with the 2VO group.

Neural Plasticity
also attenuates Aβ generation by inhibiting BACE1 activity and protects neurons against microglia-mediated Aβ neurotoxicity by suppressing NF-κB and JNK signaling [23, 25]. These indicate that TRC is a potentially effective neuroprotective agent. In future research, we will conduct systematic analyses on the anti-inflammatory effects of TRC in CCH.

N-Methyl-D-aspartate receptors (NMDARs) are fundamental to learning, memory, and excitatory postsynaptic potential. Triheteromeric NR1/NR2A/NR2B receptors constitute the major NMDARs in adult hippocampal synapses [55, 56]. NR1 is important for the maintenance of normal cognition and reduction in the NMDAR-subunit NR1 (also known as GluN1) that impairs spatial reference memory [56, 57]. The antibody against NR1 contributed to severe cognitive impairment [58]. In our study, we did not observe changes in NR1 after CCH, which suggests that NR1 is not involved in spatial learning and memory impairment after CCH. NR2A is required for memory, and attenuation of the expression of NR2A has been shown to be associated with cognitive decline [59]. Given that the level of NR2A did not change in our study, NR2A may also not be involved in CCH-induced cognitive impairment. The NMDAR subunit NR2B is important for synaptic plasticity and memory. An increase in the surface expression of NR2B has been shown to facilitate synaptic transmission and improve memory formation in vivo [60]. NR2B degradation has also been shown to impair synaptic plasticity and learning [61]. In contrast, upregulation of the expression of the NR2B subunit can enhance synaptic plasticity and memory function [62]. The current study suggests that a reduction in NR2B levels may be involved in CCH-induced spatial cognitive impairment and that TRC can upregulate the expression of NR2B. Previous studies also showed that TRC could upregulate synapse-related proteins including the NMDA receptor and improve cognition impairment in an AD transgenic model [21, 27]. This implies that TRC may improve spatial memory and synaptic plasticity by upregulating the expression of NR2B. Synapsin I is an important presynaptic protein that is located on synaptic vesicles and contributes to neurotransmitter release [63, 64], which, in turn, regulates synaptic plasticity and memory strength [65, 66]. Postsynaptic density protein 95 (PSD95) and PSD93, major...
postsynaptic proteins, are also critical for synaptic plasticity [67]. Deficient synapsin I, PSD95, and PSD93 have been shown to be associated with cognitive impairments [68–70]. In our study, synapsin I and PSD95, but not PSD93 levels were reduced by CCH. This reduction, however, was prevented by TRC treatment, which suggests that synapsin I and PSD95 may be involved in the CCH-induced cognitive impairment and the protective effects of TRC treatment.

GluR1 and GluR2 are major subunits of important excitable glutamate amino-acid-3-hydroxy-5-methyl-isoxazol-4-propionic acid receptors (AMPA Rs), which regulate synaptic plasticity and memory [71, 72]. GluR1 and GluR2 levels were not altered in our study. However, the activity of GluR2A and GluR2 is regulated by phosphorylation, and their involvement in CCH-induced cognitive impairment can therefore not be excluded. Future investigations should therefore seek to address whether GluR2A and GluR2 are involved in CCH-induced cognitive impairment.

Synaptic plasticity can mediate memory storage [73], during which new mRNA and protein syntheses are
The transcription factor CREB regulates many genes involved in synaptic plasticity and is critical for hippocampus-dependent learning and memory. Inhibition or downregulation of CREB can lead to cognitive impairment. Our studies have shown that TRC can prevent the CCH-induced inhibition of CREB, which suggests that TRC may enhance the transcription and synthesis of learning and memory-related proteins in hippocampal neurons after CCH, thereby improving synaptic plasticity and cognitive dysfunction.

Dendritic spines are postsynaptic structural components of excitatory synapses that receive excitatory input from axons at the synapse. Dendritic spines mediate transmission of electrical signals to the neuron. They contain NMDA receptors and AMPA receptors. The dendritic spine geometry is AMPA receptor and NMDA receptor-dependent Ca$^{2+}$ signaling currents in dendrites. In our study, we observed a reduction in the expression of the NMDA receptor subunit NR2A. This suggests that the level of NR2A in the dendritic spine may be reduced, which would thus affect the excitatory signal current that is mediated by the dendritic spine. To our knowledge, however, this has not yet been investigated, and further experiments are needed for clarification. Dendritic spines are also important sites for neuronal plasticity and synaptic activity that induces hippocampal dendritic morphogenesis. Long-term enhancement of hippocampal synaptic efficacy promotes the formation of new spines while...
5. Conclusion

We found that TRC can improve spatial learning, memory, and synaptic plasticity; upregulate the expression of several synaptic proteins; and increase the density of dendritic spines. Our findings suggest that administration of TRC may be an important therapy for the treatment of CCH-induced cognitive impairment.

Data Availability

The datasets in the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest

All authors declare that there are no conflicts of interest.

Authors’ Contributions

Y-ZH designed the study. Y-ZH, Y-XL, Z-SF, and J-CH performed the experiments and data collection. ZY provided critical suggestions for the experiments. Y-ZH and Y-XL analyzed the data and prepared the manuscript. All authors approved the manuscript.

Acknowledgments

This work was supported in part by grants from the National Natural Science Foundation of China (NSFC) (81400891) and the Guiding Fund of Renmin Hospital of Wuhan University (RMYD2018M31).

References

[1] J. Duncombe, A. Kitamura, Y. Hase, M. Ihara, R. N. Kalaria, and K. Horsburgh, "Chronic cerebral hypoperfusion: a key mechanism leading to vascular cognitive impairment and dementia. Closing the translational gap between rodent models and human vascular cognitive impairment and dementia," Clinical Science (London, England), vol. 131, no. 19, pp. 2451–2468, 2017.

[2] S.-Q. Du, X.-R. Wang, L.-Y. Xiao et al., "Molecular mechanisms of vascular dementia: what can be learned from animal models of chronic cerebral hypoperfusion?", Molecular Neurobiology, vol. 54, no. 5, pp. 3670–3682, 2017.

[3] M. Z. Li, Y. Zhang, H. Y. Zou et al., "Xiaoshuan enteric-coated capsule alleviates cognitive impairment by enhancing hippocampal glucose metabolism, hemodynamics and neuroplasticity of rat with chronic cerebral hypoperfusion," Scientific Reports, vol. 8, no. 1, p. 7449, 2018.

[4] J. Shang, T. Yamashita, Y. Zhai et al., "Strong impact of chronic cerebral hypoperfusion on neurovascular unit, cerebrovascular remodeling, and neurovascular trophic coupling in Alzheimer’s disease model mouse," Journal of Alzheimer’s Disease, vol. 52, no. 1, pp. 113–126, 2016.

[5] M. A. Daulatzai, "Cerebral hypoperfusion and glucose hypometabolism: key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer’s disease," Journal of Neuroscience Research, vol. 95, no. 4, pp. 943–972, 2017.

[6] D. Zhang, Y. Xiao, P. Ly et al., "Edaravone attenuates oxidative stress induced by chronic cerebral hypoperfusion injury: role of ERK/Nrf2/HO-1 signaling pathway," Neurological Research, vol. 40, no. 1, pp. 1–10, 2018.

[7] Y. Zhao and C. X. Gong, "From chronic cerebral hypoperfusion to Alzheimer-like brain pathology and neurodegeneration," Cellular and Molecular Neurobiology, vol. 35, no. 1, pp. 101–110, 2015.

[8] J. Shang, T. Yamashita, Y. Zhai et al., "Acceleration of NLRP3 inflammasome by chronic cerebral hypoperfusion in Alzheimer’s disease model mouse," Neuroscience Research, 2018.

[9] Y. Zhai, T. Yamashita, Y. Nakano et al., "Chronic cerebral hypoperfusion accelerates Alzheimer’s disease pathology with cerebrovascular remodeling in a novel mouse model," Journal of Alzheimer’s Disease, vol. 53, no. 3, pp. 893–905, 2016.

[10] S. H. Su, Y. F. Wu, D. P. Wang, and J. Hai, "Inhibition of excessive autophagy and mitophagy mediates neuroprotective effects of URB597 against chronic cerebral hypoperfusion," Cell Death & Disease, vol. 9, no. 7, p. 733, 2018.

[11] J. Miyanoahara, M. Kakae, K. Nagayasu et al., "TRPM2 channel aggravates CNS inflammation and cognitive impairment via activation of microglia in chronic cerebral hypoperfusion," The Journal of Neuroscience, vol. 38, no. 14, pp. 3520–3533, 2018.

[12] L. Feng, J. Gao, Y. Wang, Y. K. Cheong, G. Ren, and Z. Yang, “Etidronate-zinc complex ameliorated cognitive and synaptic plasticity impairments in 2-vessel occlusion model rats by reducing neuroinflammation,” Neuroscience, vol. 390, pp. 206–217, 2018.

[13] Q. Li, T. Zhang, J. Wang et al., "Rapamycin attenuates mitochondrial dysfunction via activation of mitophagy in experimental ischemic stroke," Biochemical and Biophysical Research Communications, vol. 444, no. 2, pp. 182–188, 2014.

[14] T. Feng, T. Yamashita, Y. Zhai et al., "Chronic cerebral hypoperfusion accelerates Alzheimer’s disease pathology with the change of mitochondrial fission and fusion proteins expression in a novel mouse model," Brain Research, vol. 1696, pp. 63–70, 2018.
[15] T. Sun, Y. J. Li, Q. Q. Tian et al., “Activation of liver X receptor β-enhancing neurogenesis ameliorates cognitive impairment induced by chronic cerebral hypoperfusion,” Experimental Neurology, vol. 304, pp. 21–29, 2018.

[16] A. Santiago, L. M. Soares, M. Schepers et al., “Roflumilast promotes memory recovery and attenuates white matter injury in aged rats subjected to chronic cerebral hypoperfusion,” Neuropharmacology, vol. 138, pp. 360–370, 2018.

[17] Y. Zhai, T. Yamashita, Y. Nakano et al., “Disruption of white matter integrity by chronic cerebral hypoperfusion in Alzheimer’s disease mouse model,” Journal of Alzheimer’s Disease, vol. 52, no. 4, pp. 1311–1316, 2016.

[18] J. Song, L. Yang, D. Nan, Q. He, Y. Wan, and H. Guo, “Histidine alleviates impairments induced by chronic cerebral hypoperfusion in mice,” Frontiers in Physiology, vol. 9, p. 662, 2018.

[19] Q. Liu, R. Radwanski, R. Babadjouni et al., “Experimental chronic cerebral hypoperfusion results in decreased pericyte coverage and increased blood–brain barrier permeability in the corpus callosum,” Journal of Cerebral Blood Flow & Metabolism, vol. 39, no. 2, pp. 240–250, 2018.

[20] W. Li, H. Yuan, Y. Yu, Y. K. Cheong, G. Ren, and Z. Yang, “Etidronate rescues cognitive deficits through improving synaptic transmission and suppressing apoptosis in 2-vessel occlusion model rats,” Journal of Neurochemistry, vol. 140, no. 3, pp. 476–484, 2017.

[21] N. Lin, X. D. Pan, A. Q. Chen et al., “Tripchlorolide improves age-associated cognitive deficits by reversing hippocampal synaptic plasticity impairment and NMDA receptor dysfunction in SAMP8 mice,” Behavioural Brain Research, vol. 258, pp. 8–18, 2014.

[22] Z. Hong, G. Wang, J. Gu et al., “Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice,” The European Journal of Neuroscience, vol. 26, no. 6, pp. 1500–1508, 2007.

[23] X. D. Pan, X. C. Chen, Y. G. Zhu et al., “Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling,” Glia, vol. 57, no. 11, pp. 1227–1238, 2009.

[24] X. D. Pan, X. C. Chen, Y. G. Zhu et al., “Neuroprotective role of tripchlorolide on inflammatory neurotoxicity induced by lipopolysaccharide-activated microglia,” Biochemical Pharmacology, vol. 76, no. 3, pp. 362–372, 2008.

[25] N. Lin, L. M. Chen, X. D. Pan et al., “Tripchlorolide attenuates β-amyloid generation via suppressing PPARγ-regulated BACE1 activity in N2a/APP695 cells,” Molecular Neurobiology, vol. 53, no. 9, pp. 6397–6406, 2016.

[26] F. Q. Li, X. X. Cheng, X. B. Liang et al., “Neurotrophic and neuroprotective effects of tripchlorolide, an extract of Chinese herb Tripterygium wilfordii Hook F, on dopaminergic neurons,” Experimental Neurology, vol. 179, no. 1, pp. 28–37, 2003.

[27] Y. Zeng, J. Zhang, Y. Zhu et al., “Tripchlorolide improves cognitive deficits by reducing amyloid β and upregulating synapse-related proteins in a transgenic model of Alzheimer’s disease,” Journal of Neurochemistry, vol. 133, no. 1, pp. 38–52, 2015.

[28] Z. H. Yao, X. L. Yao, Y. Zhang, S. F. Zhang, and J. Hu, “miR-132 down-regulates methyl CpG binding protein 2 (MeCP2) during cognitive dysfunction following chronic cerebral hypoperfusion,” Current Neurovascular Research, vol. 14, no. 4, pp. 385–396, 2017.

[29] X. L. Yao, Z. H. Yao, L. Li, L. Nie, and S. F. Zhang, “Oxiracetam can improve cognitive impairment after chronic cerebral hypoperfusion in rats,” Psychiatry Research, vol. 246, pp. 284–292, 2016.

[30] R. Morris, “Developments of a water-maze procedure for studying spatial learning in the rat,” Journal of Neuroscience Methods, vol. 11, no. 1, pp. 47–60, 1984.

[31] Z. H. Yao, X. L. Yao, Y. Zhang, S. F. Zhang, and J. C. Hu, “Luteolin could improve cognitive dysfunction by inhibiting neuroinflammation,” Neurochemical Research, vol. 43, no. 4, pp. 806–820, 2018.

[32] A. A. Asuni, A. Boutajangout, D. Quartermain, and E. M. Sigurdsson, “Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements,” The Journal of Neuroscience, vol. 27, no. 34, pp. 9115–9129, 2007.

[33] H. Scholtzova, E. Do, S. Dhakal et al., “Innate immunity stimulation via toll-like receptor 9 ameliorates vascular amyloid pathology in Tg-SwDI mice with associated cognitive benefits,” The Journal of Neuroscience, vol. 37, no. 4, pp. 936–959, 2017.

[34] J. A. González-Vera, R. A. Medina, M. Martín-Fontecha et al., “A new serotonin 5-HT4 receptor antagonist with procognitive activity – importance of a halogen bond interaction to stabilize the binding,” Scientific Reports, vol. 7, no. 1, article 41293, 2017.

[35] P. V. Nguyen, T. Abel, E. R. Kandel, and R. Bourichoulade, “Strain-dependent differences in LTP and hippocampus-dependent memory in inbred mice,” Learning & Memory, vol. 7, no. 3, pp. 170–179, 2000.

[36] A. Grau, M. D. Munoz, and J. M. Delgado-Garcia, “Involvement of the CA3–CA1 synapse in the acquisition of associative learning in behaving mice,” The Journal of Neuroscience, vol. 26, no. 4, pp. 1077–1087, 2006.

[37] T. Rosenberg, S. Gal-Ben-Ari, D. C. Dieterich et al., “The roles of protein expression in synaptic plasticity and memory consolidation,” Frontiers in Molecular Neuroscience, vol. 7, p. 86, 2014.

[38] L. Caracciolo, M. Marosi, J. Mazzetti et al., “CREB controls cortical circuit plasticity and functional recovery after stroke,” Nature Communications, vol. 9, no. 1, p. 2250, 2018.

[39] A. Grau, E. Benito, J. M. Delgado-Garcia, and A. Barco, “Enhanced cAMP response element-binding protein activity increases neuronal excitability, hippocampal long-term potentiation, and classical eyeblink conditioning in alert behaving mice,” The Journal of Neuroscience, vol. 32, no. 48, pp. 17431–17441, 2012.

[40] J. Lisman, K. Cooper, M. Sehgal, and A. J. Silva, “Memory formation depends on both synapse-specific modifications of synaptic strength and cell-specific increases in excitability,” Nature Neuroscience, vol. 21, no. 3, pp. 309–314, 2018.

[41] J. F. Guzowski and L. J. McGaugh, “Antisense oligodeoxynucleotide-mediated disruption of hippocampal cAMP response element binding protein levels impair consolidation of memory for water maze training,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 6, pp. 2693–2698, 1997.

[42] R. T. Hansen III and H.-T. Zhang, “Senescent-induced dysregulation of cAMP/CREB signaling and correlations with cognitive decline,” Brain Research, vol. 1516, pp. 93–109, 2013.
Neural Plasticity

[43] J.-Y. Zhang, T.-H. Liu, Y. He et al., "Chronic stress remodels synapses in an amygdala circuit-specific manner," Biological Psychiatry, vol. 85, no. 3, pp. 189–201, 2019.

[44] P. K. Stanton, "LTD, LTP, and the sliding threshold for long-term synaptic plasticity," Hippocampus, vol. 6, no. 1, pp. 35–42, 1996.

[45] J. D. Sweatt, "Neural plasticity and behavior - sixty years of conceptual advances," Journal of Neurochemistry, vol. 139, Supplement 2, pp. 179–199, 2016.

[46] T. H. Brown, P. F. Chapman, E. W. Kairiss, and C. L. Keenan, "Long-term synaptic potentiation," Science, vol. 242, no. 4879, pp. 724–728, 1988.

[47] F. L. Huang, K. P. Huang, J. Wu, and C. Boucheron, "Environmental enrichment enhances neurogranin expression and hippocampal learning and memory but fails to rescue the impairments of neurogranin null mutant mice," The Journal of Neuroscience, vol. 26, no. 23, pp. 6230–6237, 2006.

[48] T. Okada, N. Yamada, K. Tsuzuki, H. P. M. Horikawa, K. Tanaka, and S. Ozawa, "Long-term potentiation in the hippocampal CA1 area and dentate gyrus plays different roles in spatial learning," European Journal of Neuroscience, vol. 17, no. 2, pp. 341–349, 2003.

[49] D. A. Clayton, M. H. Mesches, E. Alvarez, P. C. Bickford, and M. D. Browning, "A hippocampal NR2B deficit can mimic age-related changes in long-term potentiation and spatial learning in the Fischer 344 rat," The Journal of Neuroscience, vol. 22, no. 9, pp. 3628–3637, 2002.

[50] M. Eslami, B. Sadeghi, and F. Goshadrou, "Chronic ghrelin administration restores hippocampal long-term potentiation and ameliorates memory impairment in rat model of Alzheimer’s disease," Hippocampus, vol. 28, no. 10, pp. 724–734, 2018.

[51] E. Edelmann, V. Lessmann, and T. Brigadski, "Pre- and post-synaptic twists in BDNF secretion and action in synaptic plasticity," Neuropharmacology, vol. 76, Part C, pp. 610–627, 2014.

[52] G. Leal, D. Comprido, and C. B. Duarte, "BDNF-induced local protein synthesis and synaptic plasticity," Neuropharmacology, vol. 76, Part C, pp. 639–656, 2014.

[53] L. Wang, Y. Du, K. Wang, G. Xu, S. Luo, and G. He, "Chronic cerebral hypoperfusion induces memory deficits and facilitates Aβ generation in C57BL/6j mice," Experimental Neurology, vol. 283, Part A, pp. 353–364, 2016.

[54] J. Zhang, Y. Q. Zeng, J. Zhang et al., "Tripchlorolide ameliorates experimental autoimmune encephalomyelitis by down-regulating ERK1/2-NF-κB and JAK/STAT signaling pathways," Journal of Neurochemistry, vol. 133, no. 1, pp. 104–112, 2015.

[55] C. Rauner and G. Kohr, "Triheteromeric NR1/NR2A/NR2B receptors constitute the major N-methyl-D-aspartate receptor population in adult hippocampal synapses," The Journal of Biological Chemistry, vol. 286, no. 9, pp. 7558–7566, 2011.

[56] S. R. Das, R. Jensen, R. Kelsey et al., "Reducing expression of GluN1(0XX) subunit splice variants of the NMDA receptor interferes with spatial reference memory," Behavioural Brain Research, vol. 230, no. 2, pp. 317–324, 2012.

[57] S. R. Das and K. R. Magnusson, "Changes in expression of splice cassettes of NMDA receptor GluN1 subunits within the frontal lobe and memory in mice during aging," Behavioural Brain Research, vol. 222, no. 1, pp. 122–133, 2011.

[58] R. Fleischmann, H. Prüss, B. Rosche et al., "Severe cognitive impairment associated with intrathecal antibodies to the NR1 subunit of the N-methyl-D-aspartate receptor in a patient with multiple sclerosis," JAMA Neurology, vol. 72, no. 1, pp. 96–99, 2015.

[59] J. A. McQuail, B. S. Beas, K. B. Kelly et al., "NR2A-containing NMDARs in the prefrontal cortex are required for working memory and associated with age-related cognitive decline," The Journal of Neuroscience, vol. 36, no. 50, pp. 12537–12548, 2016.

[60] F. Plattner, A. Hernández, T. M. Kistler et al., "Memory enhancement by targeting Cdk5 regulation of NR2B," Neuron, vol. 81, no. 5, pp. 1070–1083, 2014.

[61] A. H. Hawsali, D. R. Benavides, C. Nguyen et al., "Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation," Nature Neuroscience, vol. 10, no. 7, pp. 880–886, 2007.

[62] D. Wang, S. A. Jacobs, and J. Z. Tsien, "Targeting the NMDA receptor subunit NR2B for treating or preventing age-related memory decline," Expert Opinion on Therapeutic Targets, vol. 18, no. 10, pp. 1121–1130, 2014.

[63] S. Hifiker, V. A. Pieribone, A. J. Czernik, H. T. Kao, G. J. Augustine, and P. Greengard, "Synapsins as regulators of neurotransmitter release," Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, vol. 354, no. 1381, pp. 269–279, 1999.

[64] T. C. Sudhof, "The synaptic vesicle cycle," Annual Review of Neuroscience, vol. 27, no. 1, pp. 509–547, 2004.

[65] J. Sun, P. Bronk, X. Liu, W. Han, and T. C. Sudhof, "Synapsins regulate use-dependent synaptic plasticity in the calyx of Held by a Ca2+/calmodulin-dependent pathway," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 8, pp. 2880–2885, 2006.

[66] T. Niewalda, B.Michels, R. Jungnickel et al., "Synapsin determines memory strength after punishment- and relief-learning," The Journal of Neuroscience, vol. 35, no. 19, pp. 7487–7502, 2015.

[67] F. J. Bustos, E. Ampuero, N. Jury et al., "Epigenetic editing of the Dlg4/PsD95 gene improves cognition in aged and Alzheimer’s disease mice," Brain, vol. 140, no. 12, pp. 3252–3268, 2017.

[68] M. Moscoso-Castro, M. López-Cano, I. Gracia-Rubio, F. Ciruela, and O. Valverde, "Cognitive impairments associated with alterations in synaptic proteins induced by the genetic loss of adenosine A2A receptors in mice," Neuropharmacology, vol. 126, pp. 48–57, 2017.

[69] M. E. Larson, S. J. Greimel, F. Amar et al., "Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits," Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 23, pp. E4648–E4657, 2017.

[70] T. Sen, R. Gupta, H. Kaiser, and N. Sen, "Activation of PERS elicits memory impairment through inactivation of CREB and downregulation of PSD95 after traumatic brain injury," The Journal of Neuroscience, vol. 37, no. 24, pp. 9504–9511, 2017.

[71] R. Holehonnur, A. J. Phensy, L. J. Kim et al., "Increasing the GluN2A/GluN2B ratio in neurons of the mouse basal and lateral amygdala inhibits the modification of an existing fear memory trace," The Journal of Neuroscience, vol. 36, no. 36, pp. 9490–9504, 2016.

[72] L. J. M. Schmitz, R. V. Klaassen, M. Ruiperez-Alonso et al., "The AMPA receptor-associated protein Shisa7 regulates
hippocampal synaptic function and contextual memory," *Elife*, vol. 6, 2017.

[73] T. Featherby, M. van den Buuse, D. I. Lubman, and A. J. Lawrence, "Persistent downregulation of hippocampal CREB mRNA parallels a Y-maze deficit in adolescent rats following semi-chronic amphetamine administration," *British Journal of Pharmacology*, vol. 154, no. 2, pp. 417–428, 2008.

[74] C. H. Bailey, D. Bartsch, and E. R. Kandel, "Toward a molecular definition of long-term memory storage," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 24, pp. 13445–13452, 1996.

[75] A. J. Silva, J. H. Kogan, P. W. Frankland, and S. Kida, "CREB and memory," *Annual Review of Neuroscience*, vol. 21, no. 1, pp. 127–148, 1998.

[76] J. C. P. Yin and T. Tully, "CREB and the formation of long-term memory," *Current Opinion in Neurobiology*, vol. 6, no. 2, pp. 264–268, 1996.

[77] C. Pittenger, Y. Y. Huang, R. F. Paletzki et al., "Reversible inhibition of CREB/ATF transcription factors in region CA1 of the dorsal hippocampus disrupts hippocampus-dependent spatial memory," *Neuron*, vol. 34, no. 3, pp. 447–462, 2002.

[78] L. Caffino, G. Messa, and F. Fumagalli, "A single cocaine administration alters dendritic spine morphology and impairs glutamate receptor synaptic retention in the medial prefrontal cortex of adolescent rats," *Neuropharmacology*, vol. 140, pp. 209–216, 2018.

[79] M. Matsuzaki, G. C. R. Ellis-Davies, T. Nemoto, Y. Miyashita, M. Iino, and H. Kasai, "Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons," *Nature Neuroscience*, vol. 4, no. 11, pp. 1086–1092, 2001.

[80] J. Noguchi, M. Matsuzaki, G. C. R. Ellis-Davies, and H. Kasai, "Spine-neck geometry determines NMDA receptor-dependent Ca2+ signaling in dendrites," *Neuron*, vol. 46, no. 4, pp. 609–622, 2005.

[81] M. Matsuzaki, N. Honkura, G. C. R. Ellis-Davies, and H. Kasai, "Structural basis of long-term potentiation in single dendritic spines," *Nature*, vol. 429, no. 6993, pp. 761–766, 2004.

[82] Y. Fukazawa, Y. Saitoh, F. Ozawa, Y. Ohta, K. Mizuno, and K. Inokuchi, "Hippocampal LTP is accompanied by enhanced F-actin content within the dendritic spine that is essential for late LTP maintenance in vivo," *Neuron*, vol. 38, no. 3, pp. 447–460, 2003.

[83] M. Maletic-Savatic, R. Malinow, and K. Svoboda, "Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity," *Science*, vol. 283, no. 5409, pp. 1923–1927, 1999.

[84] F. Engert and T. Bonhoeffer, "Dendritic spine changes associated with hippocampal long-term synaptic plasticity," *Nature*, vol. 399, no. 6731, pp. 66–70, 1999.

[85] J. N. Bourne and K. M. Harris, "Balancing structure and function at hippocampal dendritic spines," *Annual Review of Neuroscience*, vol. 31, no. 1, pp. 47–67, 2008.

[86] I. S. Stein and K. Zito, "Dendritic spine elimination: molecular mechanisms and implications," *The Neuroscientist*, vol. 25, no. 1, pp. 27–47, 2019.

[87] B. Xu, A. Sun, Y. He et al., "Loss of thin spines and small synapses contributes to defective hippocampal function in aged mice," *Neurobiology of Aging*, vol. 71, pp. 91–104, 2018.

[88] E. M. Hernández-Hernández, K. Caporal Hernandez, R. A. Vázquez-Roque et al., "The neuropeptide-12 improves recognition memory and neuronal plasticity of the limbic system in old rats," *Synapse*, vol. 72, no. 8, article e22036, 2018.